Table 2.
Summary of studies on molecular association of PD-L1 expression using the different antibody.
| No. | Pts | Region | Antibody | Cutoff | PD-L1 expression | ||
|---|---|---|---|---|---|---|---|
| Negative association | Positive association | ||||||
| Li et al. (11) | 1370 | NSCLC | China | SP142 | ≥1% and ≥50% for TPS | EGFR mutations | KRAS, BRAF, and MET mutations and ROS1 translocations |
| Azuma et al. (44) | 164 | NSCLC | Japan | Rabbit polyclonal antibodies | A median histological score value of 30 | — | EGFR mutations |
| Scheel et al. [10] | 1255 | NSCLC | German | 5H1 | ≥1% for TPS | — | TP53, KRAS, and STK11 mutations |
| Schoenfeld et al. [44] | 1586 | ADC | America | E1L3N, 22C3, 28–8, SP142, and SP263 | ≥1% and ≥50% for TPS | EGFR and STK11 mutations | KRAS, TP53, and MET mutations |
| Dong et al. [39] | 462 | ADC | China | SP142 | ≥50% for TPS | — | TP53/KRAS comutation |
| Lamberti et al. [12] | 909 | NSCLC | America | E1L3N | ≥1% for TPS | STK11, EGFR, CTNNB1, APC, and and SMARCA4 mutations; loss of CD274, PDCD1LG2, JAK2, and the 9p24.1 locus | CD274 and PDCD1LG2 copy number gain |
| Zhang et al. [46] | 568 | NSCLC | China | 22C3 and 28-8 | ≥1% for TPS | EGFR mutations | MET, RET, ROS1, and TP53 mutations and 11q13 amplification |
-: not application; ADC: adenocarcinoma; NSCLC: non-small-cell lung cancer; PD-L1: programmed cell death ligand 1; Pts: patients; TPS: tumor proportion score.